Home/Indications/Oncology/Follicular Lymphoma

Follicular Lymphoma

Oncology 10 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Oncology indication. Follicular Lymphoma has 10 FDA-approved novel treatments, led by Roche across 8 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Follicular Lymphoma Market Leaders

Companies with the most FDA-approved novel Follicular Lymphoma drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Tafasitamab

Incyte Corporation

Estimated · fresh NCT04824092

Q4 2026

Ibrutinib

Johnson & Johnson

Estimated · fresh NCT01804686

Q1 2027

Tazemetostat

Epizyme, Inc.

Estimated · fresh NCT04224493

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Follicular Lymphoma Treatments by Mechanism

Top 12 mechanisms across 51 industry trials with a known mechanism of action.

See full pipeline →

Kinase Inhibitor

18 trials 4 active 8 sponsors

CD20-directed Cytolytic Antibody

9 trials 2 active 5 sponsors

CD19-directed Chimeric Antigen Receptor

7 trials 2 active 2 sponsors

DNA

3 trials 1 active 3 sponsors

CD30-directed Immunoconjugate

1 trials 1 active 1 sponsor

Nuclear Export Inhibitor

1 trials 1 active 1 sponsor

PI3K-delta/PI3K-gamma

3 trials 1 sponsor

Thalidomide Analog

2 trials 2 sponsors

CD20

2 trials 1 sponsor

BCL-2 Inhibitor

2 trials 2 sponsors

Proteasome Inhibitor

2 trials 1 sponsor

Programmed Death Ligand-1 Blocker

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Follicular Lymphoma Clinical Pipeline by Phase

289 industry-sponsored trials across 136 sponsors

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2020-08-04	NCT03817853

Showing 62 of 62 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Johnson & Johnson	Ibrutinib	Kinase Inhibitor [EPC]	RECRUITING	2026-12-31	NCT01804686
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A1912 Injection	—	RECRUITING	2027-03	NCT06929624
Novartis	CTL019	—	RECRUITING	2027-03-31	NCT04094311
Merck	Zilovertamab vedotin	—	RECRUITING	2027-09-24	NCT05139017
Regeneron	Odronextamab	—	RECRUITING	2028-02-07	NCT06091254
Bristol-Myers Squibb	Golcadomide	—	RECRUITING	2028-04-24	NCT06911502
BeOne Medicines	Zanubrutinib	Kinase Inhibitor [EPC]	RECRUITING	2028-07	NCT05100862
Beijing InnoCare Pharma Tech Co., Ltd.	Tafasitamab	—	RECRUITING	2028-09	NCT06521255
Regeneron	Odronextamab	—	RECRUITING	2029-01-23	NCT06149286
Merck	Zilovertamab vedotin	—	RECRUITING	2029-07-02	NCT06717347
AstraZeneca	Surovatamig	—	RECRUITING	2031-11-26	NCT06549595
Merck	MK-1045	—	RECRUITING	2032-07-23	NCT07634471
Genmab	Epcoritamab	—	RECRUITING	2037-11	NCT06191744
Beijing Mabworks Biotech Co., Ltd.	Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide	—	RECRUITING	2025-03	NCT04834024
Incyte Corporation	Tafasitamab	—	ACTIVE NOT RECRUITING	2026-09-01	NCT04824092
Epizyme, Inc.	Tazemetostat	—	ACTIVE NOT RECRUITING	2027-02-13	NCT04224493
Acerta Pharma BV	acalabrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-02-22	NCT04529772
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2027-06	NCT05578976
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2028-03	NCT06508658
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2028-03-31	NCT04408638
Novartis	Tisagenlecleucel	CD19-directed Chimeric Antigen Receptor [EPC]	ACTIVE NOT RECRUITING	2028-07-25	NCT05888493
Regeneron	Odronextamab	—	ACTIVE NOT RECRUITING	2029-07-29	NCT06097364
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2029-12	NCT05409066
Kite, A Gilead Company	Axicabtagene Ciloleucel	CD19-directed Chimeric Antigen Receptor [EPC]	ACTIVE NOT RECRUITING	2030-10	NCT05371093
Roche	Mosunetuzumab	—	ACTIVE NOT RECRUITING	2026-06-30	NCT04712097
Incyte Corporation	Tafasitamab	—	ACTIVE NOT RECRUITING	2026-03-30	NCT05429268
Seagen, a wholly owned subsidiary of Pfizer	Brentuximab vedotin	CD30-directed Immunoconjugate [EPC]	ACTIVE NOT RECRUITING	2026-01-12	NCT04404283
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2025-10-13	NCT07226752
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2025-10-13	NCT04628494
Incyte Corporation	tafasitamab	—	ACTIVE NOT RECRUITING	2024-02-23	NCT04680052
Sinocelltech Ltd.	SCTB35 injection	—	NOT YET RECRUITING	2028-05	NCT07562022
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.	TQB2825 Injection	—	NOT YET RECRUITING	2028-10	NCT07187960
Roche	Polatuzumab Vedotin	—	COMPLETED	2026-04-30	NCT03274492
Roche	Polatuzumab Vedotin	—	COMPLETED	2024-11-29	NCT04182204
Incyte Corporation	Rituximab (RTX)	—	COMPLETED	2024-06-21	NCT02763319
Bristol-Myers Squibb	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2024-04-30	NCT01476787
Pharmacyclics LLC.	Ibrutinib Oral Capsule	—	COMPLETED	2024-02-21	NCT02947347
Chipscreen Biosciences, Ltd.	R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)	—	COMPLETED	2023-01-10	NCT04231448
Dr. Reddy's Laboratories Limited	DRL_RI (Proposed rituximab biosimilar)	—	COMPLETED	2022-09-28	NCT03976102
Denovo Biopharma LLC	Enzastaurin Hydrochloride	—	COMPLETED	2022-08-11	NCT03263026
Shanghai Institute Of Biological Products	SIBP-02	—	COMPLETED	2022-05-20	NCT04361279
CTI BioPharma	Pixantrone + Rituximab	—	COMPLETED	2018-06-28	NCT01321541
Celltrion	CT-P10	—	COMPLETED	2018-01-04	NCT02260804
Pfizer	PF-05280586	—	COMPLETED	2017-10-23	NCT02213263
Mabion SA	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2017-08	NCT02617485
Novartis	Everolimus	Kinase Inhibitor [EPC]	COMPLETED	2016-06-15	NCT00790036
mAbxience Research S.L.	RTXM83	—	COMPLETED	2016-05	NCT02268045
Novartis	GP2013	—	COMPLETED	2015-07-10	NCT01419665
Bristol-Myers Squibb	Lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2013-07-04	NCT01197560
MEI Pharma, Inc.	Zandelisib	—	TERMINATED	2023-03-20	NCT04745832
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2022-09-27	NCT02536300
TG Therapeutics, Inc.	Ublituximab	—	TERMINATED	2022-05-31	NCT02793583
Pfizer	Avelumab	Programmed Death Ligand-1 Blocker [EPC]	TERMINATED	2019-12-02	NCT02951156
JHL Biotech, Inc.	JHL1101	—	TERMINATED	2019-03-07	NCT03670901
SecuraBio	Duvelisib	PI3K-delta/PI3K-gamma	TERMINATED	2016-12	NCT02204982
Roche	Rituximab	CD20-directed Cytolytic Antibody [EPC]	TERMINATED	2016-04-29	NCT01287741
Spectrum Pharmaceuticals, Inc	Zevalin	CD20	TERMINATED	2014-10-23	NCT01510184
Spectrum Pharmaceuticals, Inc	Zevalin	CD20	TERMINATED	2013-03-05	NCT01662102
Incyte Corporation	parsaclisib	—	WITHDRAWN	2028-12-20	NCT04796922
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Cyclophosphamide	DNA	WITHDRAWN	2031-10-16	NCT06313996
Shanghai Henlius Biotech	HLX01	—	WITHDRAWN	2022-04	NCT04671420
SecuraBio	Duvelisib	PI3K-delta/PI3K-gamma	WITHDRAWN	2016-11	NCT02576275

Showing 100 of 129 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
BeOne Medicines	BGB-16673	—	RECRUITING	2026-11	NCT05006716
Pell Bio-Med Technology Co., Ltd.	CD19-targeted chimeric antigen receptor T-cell	—	RECRUITING	2026-12-31	NCT05326243
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	RECRUITING	2027-01-31	NCT06806033
Vironexis Biotherapeutics Inc.	—	—	RECRUITING	2027-06	NCT06533579
AstraZeneca	Surovatamig	—	RECRUITING	2027-11-24	NCT06526793
Evopoint Biosciences Inc.	XNW5004 tablets	—	RECRUITING	2027-12-31	NCT07545603
ModeX Therapeutics, An OPKO Health Company	MDX2003	—	RECRUITING	2028-01	NCT07249905
TICAROS Co., Ltd.	TC011	—	RECRUITING	2028-02-11	NCT07473167
Merck	Nemtabrutinib	—	RECRUITING	2029-01-04	NCT04728893
BeiGene	BGB-16673	—	RECRUITING	2029-01-31	NCT05294731
Merck	Zilovertamab vedotin	—	RECRUITING	2029-03-31	NCT06395103
AstraZeneca	Acalabrutinib	Kinase Inhibitor [EPC]	RECRUITING	2029-04-22	NCT05952024
Enterome	EO2463	—	RECRUITING	2029-05-30	NCT04669171
CRISPR Therapeutics AG	CTX112	—	RECRUITING	2030-01	NCT05643742
Dizal Pharmaceuticals	DZD8586+R-CHOP	—	RECRUITING	2030-10	NCT07059650
Ascentage Pharma Group Inc.	APG-115	—	RECRUITING	2026-05-31	NCT04496349
Indapta Therapeutics, INC.	IDP-023	—	RECRUITING	2025-12-30	NCT06119685
Ranok Therapeutics (Hangzhou) Co., Ltd.	RNK05047	—	RECRUITING	2025-06-01	NCT05487170
Beijing InnoCare Pharma Tech Co., Ltd.	Tafasitamab and Lenalidomide	—	RECRUITING	2025-04	NCT05552937
Miltenyi Biomedicine GmbH	Standard of Care	—	RECRUITING	2025-01-15	NCT04844866
Beijing Mabworks Biotech Co., Ltd.	Recombinant Humanized Monoclonal Antibody MIL62 Injection	—	RECRUITING	2024-01-09	NCT04110301
Curocell Inc.	CRC01	—	RECRUITING	2023-05	NCT04836507
Beijing Immunochina Medical Science & Technology Co., Ltd.	IM19 CAR-T Cells	—	RECRUITING	2022-06-04	NCT04440436
Roche	Glofitamab	—	ACTIVE NOT RECRUITING	2026-10-16	NCT03533283
Karyopharm Therapeutics Inc	Selinexor	Nuclear Export Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-12	NCT02227251
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2027-03	NCT05451810
Novartis	Rapcabtagene autoleucel single agent	—	ACTIVE NOT RECRUITING	2027-06-30	NCT03960840
Genmab	Epcoritamab (monotherapy)	—	ACTIVE NOT RECRUITING	2027-09	NCT04542824
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)	Nemtabrutinib	—	ACTIVE NOT RECRUITING	2027-09-17	NCT03162536
Genmab	rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone	—	ACTIVE NOT RECRUITING	2027-09-30	NCT04663347
Xynomic Pharmaceuticals, Inc.	Abexinostat	—	ACTIVE NOT RECRUITING	2027-12-31	NCT03600441
Tanabe Pharma Corporation	MT-2111	—	ACTIVE NOT RECRUITING	2028-08	NCT05658562
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2029-01	NCT03625037
Merck	Zilovertamab vedotin	—	ACTIVE NOT RECRUITING	2029-05-17	NCT05458297
Roche	Mosunetuzumab (IV)	—	ACTIVE NOT RECRUITING	2030-09-06	NCT04246086
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2026-06-14	NCT05660967
Monte Rosa Therapeutics, Inc	Oral MRT-2359	—	ACTIVE NOT RECRUITING	2026-05	NCT05546268
Immunitas Therapeutics	IMT-009	—	ACTIVE NOT RECRUITING	2026-01	NCT05565417
Sichuan Baili Pharmaceutical Co., Ltd.	GNC-038	—	ACTIVE NOT RECRUITING	2025-12	NCT05192486
Incyte Biosciences Japan GK	tafasitamab	—	ACTIVE NOT RECRUITING	2025-07-01	NCT04661007
Shanghai Blueray Biopharma Co., Ltd.	BR1733	—	ACTIVE NOT RECRUITING	2025-05	NCT05749549
Shanghai Ming Ju Biotechnology Co., Ltd.	Relmacabtagene Autoleucel	—	ACTIVE NOT RECRUITING	2024-01-21	NCT06093841
Jiangsu HengRui Medicine Co., Ltd.	SHR2554	—	NOT YET RECRUITING	2027-04	NCT06368167
TICAROS Co., Ltd.	TC011 single-arm	—	NOT YET RECRUITING	2028-05-31	NCT07360288
Guangzhou Lupeng Pharmaceutical Company LTD.	Lacutoclax+Rocbrutinib	—	NOT YET RECRUITING	2029-06-30	NCT07609862
Innovent Biologics (Suzhou) Co. Ltd.	Sintilimab	—	NOT YET RECRUITING	2025-12-31	NCT05280626
XEME Biopharma Inc.	Oncoquest-L vaccine	—	NOT YET RECRUITING	2024-06	NCT02194751
Epizyme, Inc.	Tazemetostat	—	COMPLETED	2025-09-26	NCT02875548
Roche	Mosunetuzumab Intravenous (IV)	—	COMPLETED	2025-08-07	NCT03677154
Kite, A Gilead Company	Axicabtagene ciloleucel	CD19-directed Chimeric Antigen Receptor [EPC]	COMPLETED	2024-12-20	NCT03105336
Hutchmed	Tazemetostat	—	COMPLETED	2024-11-30	NCT05467943
Cyteir Therapeutics, Inc.	CYT-0851	—	COMPLETED	2024-11-30	NCT03997968
BeiGene	BGB-10188	—	COMPLETED	2024-08-28	NCT04282018
Hutchison Medipharma Limited	HMPL-689	—	COMPLETED	2024-02-29	NCT04849351
Kite, A Gilead Company	Axicabtagene Ciloleucel	CD19-directed Chimeric Antigen Receptor [EPC]	COMPLETED	2023-07-27	NCT02348216
TCR2 Therapeutics	TC-110 T Cells	—	COMPLETED	2023-02-24	NCT04323657
MorphoSys AG	Tafasitamab	—	COMPLETED	2022-11-14	NCT02399085
Nordic Nanovector	10 MBq/kg Betalutin	—	COMPLETED	2022-10-25	NCT01796171
Epizyme, Inc.	Tazemetostat	—	COMPLETED	2021-08-24	NCT01897571
Debiopharm International SA	Debio 1562	—	COMPLETED	2021-01-13	NCT02564744
AstraZeneca	Cerdulatinib	—	COMPLETED	2020-12-15	NCT01994382
Novartis	tisagenlecleucel	CD19-directed Chimeric Antigen Receptor [EPC]	COMPLETED	2020-11-24	NCT03568461
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-08-28	NCT03520920
Acerta Pharma BV	Acalabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-07-14	NCT02362035
Acerta Pharma BV	Acalabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-06-01	NCT02328014
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	COMPLETED	2019-05-24	NCT03145064
Pharmacyclics LLC.	PCI-32765	—	COMPLETED	2019-04-26	NCT01109069
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2018-05-02	NCT01282424
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2017-11	NCT02401048
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2017-11	NCT01980654
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2017-03-08	NCT01691898
Bristol-Myers Squibb	CC-223	—	COMPLETED	2016-11-15	NCT01177397
Novartis	HSC835	—	COMPLETED	2016-10-03	NCT01474681
Roche	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2016-09-27	NCT02187861
Sanofi	SAR3419	—	COMPLETED	2016-09	NCT01472887
Zhejiang Hisun Pharmaceutical Co. Ltd.	HS006+CHOP	—	COMPLETED	2016-08-12	NCT03485118
MedImmune LLC	MEDI-551 2 mg/kg	—	COMPLETED	2016-07-11	NCT01453205
Millennium Pharmaceuticals, Inc.	IXAZOMIB	—	COMPLETED	2016-06-01	NCT01939899
Ionis Pharmaceuticals, Inc.	IONIS-STAT3Rx	—	COMPLETED	2016-03-23	NCT01563302
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2015-08	NCT01306643
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2015-05	NCT01647971
Millennium Pharmaceuticals, Inc.	Alisertib (MLN8237)	—	COMPLETED	2015-02-05	NCT01397825
Amgen Research (Munich) GmbH	Blinatumomab	CD19/CD3	COMPLETED	2014-07	NCT01741792
AstraZeneca	Fostamatinib	—	COMPLETED	2013-10	NCT01499303
Pharmatech	bendamustine	—	COMPLETED	2013-08	NCT00831597
Sanofi	SAR3419	—	COMPLETED	2013-07	NCT01470456
Gilead	veltuzumab	—	COMPLETED	2013-03	NCT00546793
Millennium Pharmaceuticals, Inc.	VELCADE	Proteasome Inhibitor [EPC]	COMPLETED	2012-06	NCT01040871
SymBio Pharmaceuticals	SyB L-0501	—	COMPLETED	2011-10	NCT01118845
Millennium Pharmaceuticals, Inc.	rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2011-02	NCT00715208
Millennium Pharmaceuticals, Inc.	Alisertib	—	COMPLETED	2011-01-04	NCT00807495
Millennium Pharmaceuticals, Inc.	VELCADE	Proteasome Inhibitor [EPC]	COMPLETED	2010-05	NCT00636792
Pfizer	maplirpacept (PF-07901801)	—	TERMINATED	2026-04-09	NCT05896163
Antengene Corporation	ATG-010	—	TERMINATED	2024-12-31	NCT05265975
Zhejiang DTRM Biopharma	DTRM-555	—	TERMINATED	2024-12-31	NCT04305444
Pfizer	Maplirpacept	—	TERMINATED	2024-08-12	NCT05626322
IGM Biosciences, Inc.	imvotamab	—	TERMINATED	2024-02-16	NCT04082936
ADC Therapeutics S.A.	Loncastuximab Tesirine	—	TERMINATED	2024-01-22	NCT05144009
BioNova Pharmaceuticals (Shanghai) LTD.	BN301	—	TERMINATED	2023-12-25	NCT05611853
MingSight Pharmaceuticals, Inc	MS-553	—	TERMINATED	2023-11-28	NCT05720052

Showing 97 of 97 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Iksuda Therapeutics Ltd.	IKS03	—	RECRUITING	2026-09	NCT05365659
ADC Therapeutics S.A.	Loncastuximab Tesirine	—	RECRUITING	2026-12	NCT05660395
Nurix Therapeutics, Inc.	NX-5948	—	RECRUITING	2027-01	NCT05131022
AbbVie	ABBV-319	—	RECRUITING	2027-02	NCT05512390
GenomeFrontier Therapeutics TW Co., Ltd.	GF-CART01	—	RECRUITING	2027-03	NCT06703892
Eli Lilly	LY4584180	—	RECRUITING	2027-04	NCT07226843
Carna Biosciences, Inc.	Docirbrutinib	—	RECRUITING	2027-09	NCT05602363
Schrödinger, Inc.	SGR-1505	—	RECRUITING	2027-11	NCT05544019
Haisco Pharmaceutical Group Co., Ltd.	HSK47977	—	RECRUITING	2027-12	NCT07283796
Newave Pharmaceutical Inc	LP-168	—	RECRUITING	2027-12-31	NCT04775745
LTZ Therapeutics, Inc.	LTZ-301	—	RECRUITING	2028-02	NCT07121946
Pfizer	Mervometostat (PF-06821497)	—	RECRUITING	2028-04-20	NCT03460977
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	EXS73565	—	RECRUITING	2028-06	NCT06980116
Verismo Therapeutics	SynKIR-310	—	RECRUITING	2028-09	NCT06544265
Regeneron	Odronextamab	—	RECRUITING	2029-02-16	NCT05685173
Nurix Therapeutics, Inc.	NX-2127	—	RECRUITING	2026-05	NCT04830137
OncoNano Medicine, Inc.	ONM-501	—	RECRUITING	2026-04-30	NCT06022029
Shanghai Exuma Biotechnology Ltd.	C402-CD19-CAR	—	RECRUITING	2026-03-09	NCT06830031
Chengdu FenDi Pharmaceutical Co., Ltd.	FD-001	—	RECRUITING	2026-01-24	NCT06731699
Cullinan Therapeutics Inc.	CLN-978	—	ACTIVE NOT RECRUITING	2026-11	NCT05879744
AstraZeneca	AZD0486 IV	—	ACTIVE NOT RECRUITING	2028-06-19	NCT04594642
Poseida Therapeutics, Inc.	P-CD19CD20-ALLO1	—	ACTIVE NOT RECRUITING	2029-03	NCT06014762
AbbVie	ABBV-525	—	ACTIVE NOT RECRUITING	2029-07	NCT05618028
Acepodia Biotech, Inc.	Cyclophosphamide	DNA	ACTIVE NOT RECRUITING	2026-07	NCT05653271
Synthekine	SYNCAR-001	—	ACTIVE NOT RECRUITING	2026-06-24	NCT05665062
BeOne Medicines	BGB-21447	—	ACTIVE NOT RECRUITING	2026-05	NCT05828589
Bio-Path Holdings, Inc.	L-Bcl-2 antisense oligonucleotide	—	ACTIVE NOT RECRUITING	2025-04	NCT04072458
Guangzhou Lupeng Pharmaceutical Company LTD.	Rocbrutinib	—	NOT YET RECRUITING	2027-12-31	NCT07570017
Ascentage Pharma Group Inc.	APG-3288	—	NOT YET RECRUITING	2029-12	NCT07424833
Boston Immune Technologies and Therapeutics	BITR2101	—	NOT YET RECRUITING	2026-06	NCT06385522
Juno Therapeutics, a Subsidiary of Celgene	JCAR017 (lisocabtagene maraleucel) single-dose schedule	—	COMPLETED	2024-05-16	NCT02631044
Xencor, Inc.	XmAb13676	—	COMPLETED	2024-04	NCT02924402
Sutro Biopharma, Inc.	STRO-001	—	COMPLETED	2024-02-15	NCT03424603
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Zilovertamab vedotin	—	COMPLETED	2023-12-18	NCT03833180
Boryung Pharmaceutical Co., Ltd	BR101801 (Phase Ia)	—	COMPLETED	2023-09-21	NCT04018248
Kymera Therapeutics, Inc.	KT-413	—	COMPLETED	2023-07-28	NCT05233033
Epizyme, Inc.	Tazemetostat	—	COMPLETED	2023-04-03	NCT04537715
Celldex Therapeutics	CDX-1140	—	COMPLETED	2022-09-13	NCT03329950
Nordic Nanovector	10 MBq/kg Betalutin	—	COMPLETED	2022-08-08	NCT03806179
Allogene Therapeutics	ALLO-647	—	COMPLETED	2021-10-23	NCT03939026
Novartis	Tisagenlecleucel	CD19-directed Chimeric Antigen Receptor [EPC]	COMPLETED	2021-07-20	NCT03630159
Opna Bio LLC	PLX2853	—	COMPLETED	2021-06-07	NCT03297424
Acerta Pharma BV	AZD9150	—	COMPLETED	2021-03-31	NCT03527147
MorphoSys AG	Tafasitamab	—	COMPLETED	2021-02-11	NCT04134936
Incyte Biosciences International Sàrl	INCAGN02385	—	COMPLETED	2020-10-07	NCT03538028
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2020-06-26	NCT01953692
MedImmune LLC	MEDI7247	—	COMPLETED	2020-01-03	NCT03106428
AbbVie	ABBV-075	—	COMPLETED	2019-07-05	NCT02391480
Roche	RO6870810	—	COMPLETED	2019-07-03	NCT03255096
MedImmune LLC	MEDI4736	—	COMPLETED	2019-02-04	NCT02549651
Epizyme, Inc.	Tazemetostat and [14C] Tazemetostat	—	COMPLETED	2019-01-08	NCT03010982
Novartis	BCL201	—	COMPLETED	2018-07-10	NCT02603445
Seagen Inc.	SGN-CD70A	—	COMPLETED	2017-02-15	NCT02216890
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	OTX015/Birabresib	—	COMPLETED	2017-01-20	NCT01713582
Millennium Pharmaceuticals, Inc.	Alisertib	—	COMPLETED	2016-10-01	NCT00697346
Morphotek	anti-endosialin/TEM1 monoclonal antibody MORAb-004	—	COMPLETED	2015-05	NCT01748721
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2014-12-25	NCT02242045
Bristol-Myers Squibb	BMS-936564 (Anti-CXCR4)	—	COMPLETED	2014-11	NCT01120457
Teva Branded Pharmaceutical Products R&D, Inc.	TL011	—	COMPLETED	2013-07	NCT01205737
Millennium Pharmaceuticals, Inc.	TAK-901	—	COMPLETED	2012-09	NCT00807677
Roche	Polatuzumab Vedotin	—	COMPLETED	2012-06-29	NCT01290549
Novartis	HCD122	—	COMPLETED	2012-05	NCT01275209
SymBio Pharmaceuticals	SyB L-0501	—	COMPLETED	2010-03	NCT00794638
Pfizer	PF-08046032	—	TERMINATED	2026-04-23	NCT06870487
Novartis	MAK683	—	TERMINATED	2024-10-09	NCT02900651
Novartis	JBH492	—	TERMINATED	2024-09-05	NCT04240704
MEI Pharma, Inc.	voruciclib monotherapy	—	TERMINATED	2024-07-24	NCT03547115
Pfizer	Maplirpacept (PF-07901801)	—	TERMINATED	2024-07-18	NCT03530683
TG Therapeutics, Inc.	TG-1801	—	TERMINATED	2024-06-12	NCT04806035
Epizyme, Inc.	EZM0414	—	TERMINATED	2024-04-30	NCT05121103
Prelude Therapeutics	PRT1419	—	TERMINATED	2024-01-19	NCT05107856
Seagen Inc.	SEA-TGT	—	TERMINATED	2023-12-01	NCT04254107
Shengke Pharmaceuticals Pty Ltd	ETH-155008	—	TERMINATED	2023-05-02	NCT04840784
MEI Pharma, Inc.	ME-401	—	TERMINATED	2023-03-29	NCT02914938
Eden BioCell Ltd.	RPM CD19-mbIL15-CAR-T cells	—	TERMINATED	2022-05-12	NCT04844086
Amgen	AMG 562	—	TERMINATED	2022-01-12	NCT03571828
Novartis	Tisagenlecleucel	CD19-directed Chimeric Antigen Receptor [EPC]	TERMINATED	2021-11-01	NCT03876028
Karyopharm Therapeutics Inc	KPT-9274	—	TERMINATED	2021-01-26	NCT02702492
ADC Therapeutics S.A.	Loncastuximab Tesirine and Durvalumab	—	TERMINATED	2020-10-27	NCT03685344
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	TERMINATED	2019-12-30	NCT03797261
Amgen	AMG 397	—	TERMINATED	2019-07-25	NCT03465540
Seagen Inc.	SGN-CD19B	—	TERMINATED	2018-07-10	NCT02702141
Merck	Birabresib Dose 20 mg	—	TERMINATED	2018-01-18	NCT02698189
Gilead	IMMU-114	—	TERMINATED	2017-03	NCT01728207
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company	DCR-MYC	—	TERMINATED	2016-10-05	NCT02110563
Gilead	GS-9901	—	TERMINATED	2015-08	NCT02258555
Merck	MK-8808	—	TERMINATED	2014-12-01	NCT01370694
Novartis	AEB071	—	TERMINATED	2014-04	NCT01402440
TG Therapeutics, Inc.	Ublituximab	—	TERMINATED	2014-02-07	NCT01744912
Celltrion	rituximab	CD20-directed Cytolytic Antibody [EPC]	TERMINATED	2013-02	NCT01534949
Astex Pharmaceuticals, Inc.	SGI-1776	—	TERMINATED	2010-10	NCT00848601
Innovent Biologics (Suzhou) Co. Ltd.	lenalidomide	Thalidomide Analog [EPC]	WITHDRAWN	2029-08-31	NCT05867030
Fate Therapeutics	FT596	—	WITHDRAWN	2026-05	NCT05934097
Spectrum Pharmaceuticals, Inc	IGN002	—	WITHDRAWN	2025-07	NCT02847949
ADC Therapeutics S.A.	Loncastuximab tesirine	—	WITHDRAWN	2024-03-11	NCT04974996
Hutchmed	HMPL-760	—	WITHDRAWN	2022-11-16	NCT05176691
Gilead	Idelalisib	Kinase Inhibitor [EPC]	WITHDRAWN	2021-02	NCT03349346

Novel Follicular Lymphoma Drugs by Company (New molecular entities)

7 companies have an FDA-approved novel drug for Follicular Lymphoma.

Roche 4 drugs

EPIZYME INC 1 drug

TAZEMETOSTAT HYDROBROMIDE

NDA 2020

BEONE MEDICINES USA 1 drug

BRUKINSA

ZANUBRUTINIB

NDA 2019

GENMAB US, INC. 1 drug

EPKINLY

EPCORITAMAB-BYSP

BLA 2023

MORPHOSYS US INC 1 drug

Novartis 1 drug

Juno Therapeutics, Inc. a Bristol Myer-Squibb Company 1 drug

Breyanzi

lisocabtagene maraleucel

BLA 2021

Reformulations (3 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Follicular Lymphoma Drug Targets

Molecular targets of approved and investigational Follicular Lymphoma drugs — 8 targets tracked.

CD20 9 CD3 3 CD19 3 PI3Kδ 2 EZH1 1 EZH2 1 Hyaluronan 1 Cereblon 1

Biosimilars (3 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

2018

Generic Drugs (1 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

IDELALISIB